BackLiminatus Pharma Class A Common Stock Overview

Liminatus Pharma Class A Common Stock Total Liabilities

Liminatus Pharma Class A Common Stock's total liabilities is $3.1M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$3.10M
↓ 71.04% YoYΔ $-7.61M vs prior year quarter

Peer trimmed avg / median

Loading

Liminatus Pharma Class A Common Stock Total Liabilities History

Loading

Liminatus Pharma Class A Common Stock vs. peers: Total Liabilities Comparison

Loading

Liminatus Pharma Class A Common Stock Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Liminatus Pharma Class A Common Stock (LIMN) FAQ

As of the most recent data (June 2026), LIMN shows a total liabilities of $3.1M. That compares with $11M in the prior-year period — down 71.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LIMN's total liabilities is now $3.1M (was $11M) — a 71.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Liminatus Pharma Class A Common Stock is outperforming or lagging.

Tracking LIMN's total liabilities over time shows whether Liminatus Pharma Class A Common Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $3.1M That compares with $11M in the prior-year period — down 71.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Liminatus Pharma Class A Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $3.1M) with ownership activity and broader fundamentals.